GPM Reminds Investors of the August 1 Deadline in the Class Action Lawsuit Against TransEnterix, Inc.

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the August 1, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the “Class”) of investors who purchased TransEnterix, Inc. (“TransEnterix” or the “Company”) (NYSE: TRXC) securities between February 10, 2016 and May 10, 2016, inclusive (the “Class Period”). TransEnterix investors have until August 1, 2016 to file a lead plaintiff motion.

On April 20, 2016, TransEnterix disclosed that its SurgiBot System failed to meet the United States Food and Drug Administration’s (the “FDA”) standards for substantial equivalence based upon the data and information TransEnterix submitted in its 510(k) filing.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: there were deficiencies within the Company's 510(k) submission regarding the SurgiBot that undermined the likelihood that the SurgiBot would receive FDA clearance, which would leave the Company unable to commercialize the SurgiBot in 2016 and would impair the Company's ability to obtain approval for and commercialize its other robotic surgery platform in the United States.

If you purchased TransEnterix shares, you may move the Court no later than August 1, 2016 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160729005795/en/